Orthofix Medical Inc. (OFIX)

From the record

Orthofix Medical Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Orthofix Medical Inc.'s 10 filed years say what it did: revenue went from $410 million in fiscal 2016 to $822 million in fiscal 2025, up 8% a year; it rose in 7 of 9 years; the deepest fall was 12% from fiscal 2019 to fiscal 2020; net income was positive in 4 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Orthofix Medical Inc.'s diluted share count grew about 25.5% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 24 sales (3 under scheduled 10b5-1 plans) and 4 purchases of their own stock on the open market in the year to 2026-11-12, buying about $124 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Orthofix Medical Inc. lost about 20 cents for every dollar of shareholders' money, and gross profitability: its products earned about 67 cents per dollar of everything the company owns. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 3.9% over the year (the filed statements).

From the record

Orthofix Medical Inc.'s standing among 109 graded names in its industry family: revenue of $822 million in fiscal 2025 ranks in the top 21% by size; a net margin of -11.2% ranks in the top 42%; revenue growth of 21.3% a year over the last 3 filed years ranks in the top 37% (its annual reports).

From the record

Orthofix Medical Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Calafiore, Massimo (President & CEO, as filed), filing under that title since 2024-01-10, 2.8 years (bottom 40% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 2.9 years (bottom 12%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Orthofix Medical Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $82 million against debt of $157 million leaves -8.9% of its assets as net cash, bottom 28% of its family; cash from operations less capital spending is -0.2% of revenue (top 43%); a gross margin of 68.8% (top 34%); research spending of 8% of revenue (bottom 36%) (its annual report).

From the record

Orthofix Medical Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 21.3% a year over the last three filed years against 8% over all 10, speeding up (top 10% of its family); the newest year grew 2.9% (bottom 27%); research spending grew 10.3% a year (top 35%); capital spending grew 14.3% a year (top 31%) (its annual reports). Orthofix Medical Inc. reported 2 lines of business in fiscal 2025: Global Spine at $688 million (84%), Global Limb Reconstruction at $135 million (16%); 2 of 2 grew against the year before (its annual report).

From the record

Orthofix Medical Inc.'s newest year against its own record: revenue of $822 million in fiscal 2025 came in 21.9% below the $1.1 billion its prior three years' pace pointed to (bottom 19% of its family); net income of $92 million against a prior three-year average of $99 million (bottom 42%); a net margin of -11.2% against -13.4% before (bottom 32%) (its annual reports).